GSK will enlist regulatory RNA biotech Camp4 Therapeutics to help find and create new neurodegenerative and kidney disease medicines.
The deal is worth $17.5 million upfront, and as much as $440 million in development and …
A US congressional commission is escalating its warning that the US could soon be eclipsed by China in biotech, after lawmakers took up some of
The head of a UK government committee has demanded more details on how the country is planning to fund the higher prices it will pay
Thanks to CEPI, Moderna’s H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by
The FDA placed a partial hold on Daiichi Sankyo and Merck’s Phase 3 study of a lung cancer drug after the companies paused enrollment for
Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
GSK will enlist regulatory RNA biotech Camp4 Therapeutics to help find and create new neurodegenerative and kidney disease medicines.
The deal is worth $17.5 million upfront, and as much as $440 million in development and …